FDA vs. EMA IVRT Guidelines: Key Differences for Topical Drug Development
In vitro release testing (IVRT) supports the development and regulatory assessment of topical drug products by measuring the rate at which an active pharmaceutical ingredient (API) is released from a formulation. For generic drug development, formulation changes, and post-approval changes, IVRT data can help demonstrate comparable product performance and support regulatory submissions.
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have different expectations for IVRT studies, including the scope of applicable guidance, sample requirements, method validation, and statistical evaluation. Sponsors developing topical products for both markets must understand these differences when establishing an IVRT strategy.
CPL provides specialized IVRT and IVPT testing to support topical drug development. Understanding the applicable regulatory expectations early can help sponsors select appropriate test conditions, develop suitable methods, and reduce avoidable testing and development work.
Understanding FDA and EMA IVRT Guidelines
The FDA’s October 2022 draft guidance, In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs, addresses IVRT studies used to support bioequivalence assessments for generic topical products submitted through abbreviated new drug applications (ANDAs). Its scope includes products applied to the skin and certain mucosal membranes.
The EMA’s Guideline on Quality and Equivalence of Locally Applied, Locally Acting Cutaneous Products, published in its current form in October 2024, addresses the quality and equivalence of locally applied, locally acting cutaneous products. Its scope differs from the FDA’s ANDA-focused guidance and may be relevant to different development and regulatory scenarios.
These differences matter when determining which recommendations apply to a particular product and submission pathway. The FDA document remains draft guidance and contains nonbinding recommendations, whereas the EMA document is an adopted scientific guideline.
Sponsors should assess the applicable guidance for each market rather than assume that a method developed for one regulatory pathway will automatically satisfy the other.
IVRT Study Design: Similar Principles, Different Requirements
The FDA and EMA share fundamental expectations for IVRT study design. Both approaches use vertical diffusion cells and a synthetic membrane to separate the topical formulation from a receptor medium. Samples collected from the receptor medium are analyzed over time to determine the drug release profile.
The receptor medium must provide suitable solubility for the API and maintain sink conditions. This helps prevent drug accumulation from limiting release and distorting the measured release rate. Membrane selection, receptor medium composition, temperature, sampling conditions, and formulation application must be appropriate for the specific product and method.
Although these principles are similar, individual study parameters can differ.
Temperature Requirements Depend on the Application Site
For products applied to the skin, both agencies specify a test temperature of 32 ± 1°C. This temperature reflects the skin surface conditions relevant to the test.
The FDA’s draft guidance also addresses products applied to mucosal membranes. For those products, the specified temperature is 37 ± 1°C. The EMA guideline discussed here focuses on locally applied, locally acting cutaneous products, so its scope differs.
Sponsors developing products for different application sites should confirm the applicable temperature and other study conditions before finalizing the IVRT protocol.
Receptor Media and Membrane Selection Must Suit the Formulation
Selecting an appropriate receptor medium and synthetic membrane is central to developing a reliable IVRT method. These choices can affect drug solubility, recovery, and the measured release profile.
The method must maintain suitable sink conditions throughout the study. The FDA’s draft guidance describes a receptor medium with API solubility at least three times the highest expected concentration in the receptor solution as one way to support sink conditions.
Method development should also establish that the membrane and receptor medium do not introduce limitations that obscure the formulation’s release behavior.
The appropriate conditions depend on the formulation and API. A change to the formulation may require reassessment of the test system, even when the change appears minor.
IVRT Method Validation and Discriminatory Ability
An IVRT method must be suitable for its intended purpose. Validation should establish that the method generates reliable and reproducible data and can distinguish meaningful changes in formulation or product quality.
Both the FDA and EMA expect evidence that the method can discriminate between formulations with different drug concentrations. However, their recommendations differ in the specific criteria used to evaluate this capability.
Drug Concentration and Release-Rate Linearity
The relationship between drug concentration in a formulation and its release rate is an important part of method validation. When the API is fully dissolved, the EMA guideline specifies an (r^2) value of at least 0.90 for the relationship between formulation concentration and release rate.
The FDA’s draft guidance recommends a more stringent (r^2) value of at least 0.95 for the corresponding concentration-discrimination assessment. It also describes comparisons involving formulations at 50%, 100%, and 150% of the labeled drug concentration, including statistical assessments of equivalence between the lower- and higher-concentration formulations and the 100% formulation.
These criteria should not be treated as interchangeable. Sponsors should verify the applicable guidance and study context when establishing acceptance criteria for method validation.
Release-Rate Linearity Within Individual Diffusion Cells
The linearity of drug release over the sampling period is another important consideration. The FDA’s draft guidance recommends an (r^2) value of at least 0.97 for the linearity of drug release rate across time points.
This assessment differs from evaluating the relationship between formulation drug concentration and release rate. Both are relevant to method development, but they answer different questions.
A suitable IVRT method must establish a reliable release profile for individual diffusion cells while demonstrating that the method can distinguish meaningful formulation differences.
Precision and Reproducibility
Method validation should also establish consistent results across replicate measurements and relevant testing conditions. Precision and reproducibility assessments help determine whether the method can generate reliable results across runs, operators, and days.
Acceptance criteria must be established in the context of the applicable guidance and the method’s intended use. Sponsors should avoid applying a single precision threshold to every aspect of IVRT testing without confirming its relevance.
CPL’s expertise in analytical method development and validation supports the development of methods designed to evaluate product quality, stability, performance, and batch-to-batch consistency.
IVRT Sample Requirements and Statistical Evaluation
The number of samples and the statistical method used to demonstrate equivalence are important differences between FDA and EMA expectations.
Under the EMA guideline, a minimum of 12 samples per product is generally specified for the relevant equivalence assessment. The FDA’s draft guidance describes a staged approach to IVRT equivalence testing for generic topical products. In Stage 1, six individual measurements from the test product and six from the reference standard are evaluated. Additional testing may be required under the applicable procedure if the initial stage does not establish equivalence.
These differences affect study planning, resource requirements, and data analysis. Sponsors should determine the appropriate sample size and statistical approach before initiating a pivotal study, while confirming the specific requirements that apply to the intended submission.
Equivalence Criteria Are Not Directly Interchangeable
The EMA and FDA approaches use different statistical frameworks and acceptance criteria to evaluate IVRT equivalence.
The EMA guideline uses confidence intervals for the ratio of release rates, with a specified acceptance range of 90.00% to 111.11% for the relevant equivalence assessment. The FDA’s draft guidance describes an acceptance range of 75% to 133.33% for the ratio of release-rate slopes in its staged approach.
Although these ranges appear substantially different, they must be interpreted in the context of the respective statistical methods, study designs, and decision rules. Comparing the numerical ranges alone does not establish that one approach is universally more stringent than the other.
Sponsors should apply the statistical method specified for the intended regulatory pathway and document the analysis used to support the equivalence conclusion.
Planning IVRT Testing for US and European Submissions
Sponsors pursuing regulatory submissions in both the US and Europe should compare the applicable FDA and EMA expectations before finalizing their IVRT method and study protocol.
Some method parameters may need to satisfy different acceptance criteria, while others may be addressed similarly by both agencies. A method intended to support both pathways should be developed against the applicable requirements for each market, including study design, method validation, sample requirements, and statistical evaluation.
For example, a method designed to meet the FDA’s recommended release-rate linearity criterion of (r^2 \geq 0.97) would exceed the EMA guideline’s specified (r^2 \geq 0.90) criterion for the relationship between formulation concentration and release rate when the API is fully dissolved. However, this does not establish compliance with every requirement of either guideline. Each parameter must be assessed independently.
Early regulatory planning can help sponsors determine whether a common method can support both submissions or whether market-specific adjustments are necessary.
Formulation Changes Can Affect IVRT Results
IVRT methods are formulation-specific. Changes to excipients, ingredient suppliers, quantitative composition, or manufacturing conditions can affect the release profile, even when the change appears minor.
This is particularly important for post-approval changes. A sponsor may need to replace an excipient supplier because the original supplier can no longer provide material that meets the required manufacturing or quality standards. The replacement excipient may have the same nominal identity and concentration but different material characteristics that affect drug release.
In one example from CPL’s work, a sponsor needed to replace an excipient that was no longer available at the required GMP level. Although the excipient represented only approximately 1% of the formulation, material from different suppliers produced substantially different IVRT release rates.
CPL supported the formulation team in evaluating alternative excipient sources and identifying a suitable replacement that maintained a release profile comparable to the pre-change product. This work helped the sponsor assess the change before committing to manufacturing a larger batch that might not demonstrate the required equivalence.
The example illustrates why formulation changes should be evaluated using appropriate product performance testing rather than relying solely on ingredient identity or concentration.
Sponsors should establish the formulation before completing IVRT method validation whenever feasible. If the formulation changes during development, the existing method should be assessed to determine whether it remains suitable for the updated product.
CPL’s approach to reformulation for underperforming topical products demonstrates the importance of evaluating formulation characteristics and identifying changes that may affect product performance.
CPL Supports IVRT Method Development and Regulatory Submissions
Developing a suitable IVRT method requires an understanding of the formulation, the test system, the applicable regulatory expectations, and the statistical approach used to interpret the results.
CPL has supported generic drug submissions, post-approval changes, and new drug development programs involving IVRT. Its experience includes successful regulatory submissions in the US and Europe, with IVRT methods used to support product approvals and responses to agency questions.
CPL integrates Skin Lab testing with formulation development and analytical capabilities to help sponsors evaluate drug release, investigate formulation differences, and generate data for development and regulatory decisions. IVRT testing can support generic product comparisons, scale-up, manufacturing site transfers, post-approval changes, and quality control. CPL also performs in vitro permeation testing (IVPT) to support formulation development by evaluating drug permeation through a biological membrane and helping assess topical product performance.
These capabilities are part of CPL’s broader product and formulation development services, which support semi-solid drug products from preformulation and prototype development through scale-up and manufacturing.
Selecting appropriate test conditions and validating the method against the applicable regulatory expectations can help sponsors identify product performance issues before they create additional development work or manufacturing costs.
Discuss IVRT Testing Requirements With CPL
FDA and EMA IVRT expectations differ in scope, sample requirements, method validation criteria, and statistical evaluation. Sponsors must account for those differences when developing topical drug products, preparing regulatory submissions, or assessing post-approval formulation changes.
CPL provides specialized IVRT testing and method development for topical drug products, supported by expertise in formulation development, analytical testing, and manufacturing. Its scientists work with sponsors to assess product-specific challenges, establish appropriate testing strategies, and generate data to support development and regulatory objectives.
Contact CPL to schedule a meeting and discuss IVRT method development, regulatory testing requirements, or a planned formulation or manufacturing change. CPL can help determine the testing approach appropriate for the product, its development stage, and the intended regulatory pathway.